|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02186 LUYE PHARMA
Nominal 
2.130 -0.050 (-2.294%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 6,061,441 | -1.329% | 6,143,078 | 5,981,656 | 5,200,226 | 5,539,641 |
| Cost of Sales | (2,017,214) | 4.039% | (1,938,903) | (1,841,140) | (1,803,486) | (1,549,027) |
| Gross Profit | 4,044,227 | -3.805% | 4,204,175 | 4,140,516 | 3,396,740 | 3,990,614 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (774) | -- | 794 | 831 | 701 | 1,726 | |
| Profit / (Loss) before Taxation | 839,219 | 19.871% | 700,100 | 669,762 | (74,557) | 942,174 | |
| Taxation | (194,211) | 20.611% | (161,023) | (86,466) | (70,226) | (238,909) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (173,122) | 2574.938% | (6,472) | 21,511 | 10,391 | 3,321 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 471,886 | -11.400% | 532,605 | 604,807 | (134,392) | 706,586 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 477,353 | -14.501% | 558,317 | 383,082 | 297,462 | 313,597 |
| Depreciation & Amortisation | 790,672 | 12.655% | 701,851 | 671,313 | 581,982 | 510,899 |
| Directors' Emoluments | -- | -- | 11,788 | 10,218 | 10,694 | 12,176 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 12.540 | -12.246% | 14.290 | 17.380 | -3.900 | 22.170 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.428 | 0.475 | 0.053 | 0.324 |
| NBV per share ($) | 3.640 | -- | 3.229 | 2.867 | 2.314 | 2.339 |
| Remarks: | Real time quote last updated: 03/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 471,886 |
| %Change | -11.400% |
| EPS / (LPS) | RMB 0.125 |
| NBV Per Share (¥) | RMB 3.640 |